More Information About - Trizon 500 i/v ial Inj. 500mg/vial
Description
Generic Name
Ceftriaxone
Precaution
History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.
Lactation: Drug enters breast milk in low concentrations; use with caution
Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.
Dose
N/A
Side Effect
>10%
Induration after IM injection (5-17%)
1-10%
Eosinophilia (6%),Thrombocytosis (5%),Diarrhea (3%),Elevated hepatic transaminases (3%),Leukopenia (2%),Rash (2%),Increased blood urea nitrogen (BUN) (1%),Induration at IV site (1%),Pain (1%)
<1%
Agranulocytosis,Anaphylaxis,Anemia,Basophilia,Bronchospasm,Candidiasis,Chills,Diaphoresis,Dizziness,Dysgeusia,Flushing,Gallstones,Glycosuria,Headache,Hematuria,Hemolytic anemia,Increased alkaline phosphatase or bilirubin,Increased creatinine,Jaundice,Leukocytosis,Lymphocytosis,Lymphopenia,Monocytosis,Nausea,Neutropenia,Phlebitis,Prolonged or decreased prothrombin time (PT),Pruritus,Renal stones,Serum sickness,Thrombocytopenia,Urinary casts,Vaginitis,Vomiting
Pregnancy Category
Name :
B
Description
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.
Mode of Action
Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Interaction
May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
Pregnancy Category Note
Pregnancy category: B
Lactation: Drug enters breast milk in low concentrations; use with caution
Adult Dose
Susceptible infections IV/IM 1-2 g/day, up to 4 g/day for severe infections.
Intra-abdominal Infections
Complicated, mild-to-moderate, community acquired: 1-2 g/day IV in single daily dose or divided q12hr for 4-7 days, in combination with metronidazole
Meningitis
2 g IV q12hr for 7-14 days
Acute Uncomplicated Pyelonephritis
1-2 g IV qDay
Typhoid fever
2 g IV once daily for 14 days.
Surgical Prophylaxis
Prophylaxis of surgical infection
1 g IV 0.5-2 hours before procedure
Uncomplicated Gonococcal Infections
Uncomplicated gonococcal infection of pharynx, cervix, urethra, or rectum: ceftriaxone 250 mg IM once plus azithromycin 1 g PO once (preferred) or alternatively, doxycycline 100 mg PO q12hr for 7 days
Pelvic Inflammatory Disease
250 mg IM as single dose with doxycycline, with or without metonidazole for 14 days
Child Dose
Children: IV, IM: 50?75 mg/kg/day, max 2 g/day q24h
50 mg/kg, max 1 g, 1?3 doses IM for AOM q24h
100 mg/kg/day for meningitis, max 4 g/day q12h
Renal Dose
Renal impairment:
CrCl (ml/min)
<10 Max: 2 g daily.
Administration
IV/IM Administration
IV: Infuse intermittently over 30 minutes
IM: Inject deep into large muscle mass
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.